Current and future challenges in therapy for antibody-mediated rejection.
about
Exercise-based cardiac rehabilitation in heart transplant recipientsImmunologic considerations in heart transplantation for congenital heart diseaseInduction therapy in heart transplantation: where are we now?The Complement System and Antibody-Mediated Transplant RejectionAntibody-mediated rejection: an evolving entity in heart transplantation.Exercise-based cardiac rehabilitation in heart transplant recipients.Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells.Heart transplantation research in the next decade--a goal to achieving evidence-based outcomes: National Heart, Lung, And Blood Institute Working GroupSignificance of Anti-HLA Antibodies on Adult and Pediatric Heart Allograft Outcomes.Heart transplantation: challenges facing the field.Improving survival during heart transplantation: diagnosis of antibody-mediated rejection and techniques for the prevention of graft injury.Rituximab is associated with improved survival in cardiac allograft patients with antibody-mediated rejection: a single center review.Human leukocyte antigens and alloimmunization in heart transplantation: an open debate.Immunosuppression and adult heart transplantation: emerging therapies and opportunities.Permanent CNI treatment for prevention of renal allograft rejection in sensitized hosts can be replaced by regulatory T cells.C4d immunostaining is an independent predictor of cardiac allograft vasculopathy and death in heart transplant recipients.A survey of current practice for antibody-mediated rejection in heart transplantation.
P2860
Q26471613-2DEFF73F-8247-433A-9FBA-28DCDD310777Q26995790-93BFB4FA-52E4-4D12-B36B-5CF18190B51AQ26999269-4707BA29-EE88-44AA-97F1-3AECFCAD3263Q28087773-EA4A4E25-D530-47E9-9B56-87030788C4E1Q35876250-5E060886-F373-43D8-9D9C-C737342E118BQ36333896-F07C9EBA-B9EF-4E28-B367-5FC8F3D14210Q37453921-B70B9623-F23A-4DCC-B274-98293365F81FQ37524481-6036DC9B-926F-4757-A382-9954DAFFA791Q37609092-42542016-0FAD-4776-8E54-C39533D3BD02Q37717939-81FEBE16-AC94-4C50-832A-348454DCBCD8Q38032621-F84246C0-0EF5-4ECE-9D45-15302D24C769Q38168615-8DB95E41-8A19-48D6-A944-C82BB3147377Q38246225-654DFA5B-FBD0-42F5-9EAC-80704A03F80CQ39029380-9572DB15-6110-45ED-AC8B-4085529DDBDAQ47617412-29685126-0424-4399-B815-D712D4247D85Q48215946-99375529-6CE8-4B0F-8823-138B50DFFF70Q51256229-3378F7CA-3AB2-47BF-B4F1-35EB9BD162C7
P2860
Current and future challenges in therapy for antibody-mediated rejection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current and future challenges in therapy for antibody-mediated rejection.
@en
Current and future challenges in therapy for antibody-mediated rejection.
@nl
type
label
Current and future challenges in therapy for antibody-mediated rejection.
@en
Current and future challenges in therapy for antibody-mediated rejection.
@nl
prefLabel
Current and future challenges in therapy for antibody-mediated rejection.
@en
Current and future challenges in therapy for antibody-mediated rejection.
@nl
P2093
P1476
Current and future challenges in therapy for antibody-mediated rejection.
@en
P2093
Nandini Nair
Patricia A Uber
Timothy Ball
P304
P356
10.1016/J.HEALUN.2011.02.002
P577
2011-04-07T00:00:00Z